<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195959</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-Nr. 2016-02136</org_study_id>
    <nct_id>NCT03195959</nct_id>
  </id_info>
  <brief_title>Effect of Normobaric Hypoxia and Hyperoxia in Patients With Pulmonary Hypertension</brief_title>
  <official_title>Effect of Normobaric Hypoxia and Hyperoxia on Pulmonary Hemodynamics in Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary Hypertension (PH) is a severe disease with a bad prognosis. However, thanks to&#xD;
      extensive research in this field, there are more and better treatment options that allow&#xD;
      patients to participate in recreational activities at moderate altitude or bring up the&#xD;
      question of air-travel.&#xD;
&#xD;
      Still very few is known about the effects hypoxic conditions have on PH patients. The aim of&#xD;
      this study is to investigate the effects of hypoxia in comparison to normoxia and hyperoxia&#xD;
      on pulmonary hemodynamics in patients with pulmonary hypertension during routine right heart&#xD;
      catheterisation. We aim to get insight into the pathophysiology of pulmonary hemodynamics&#xD;
      under hypoxic conditions in comparison to normoxia and hyperoxia in patients with pulmonary&#xD;
      arterial and chronic thromboembolic pulmonary hypertension compared with control patients,&#xD;
      that are scheduled for right heart catheterisation due to dyspnea but have no PH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of pulmonary vascular resistance during hypoxia in comparison to normoxia and hyperoxia</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of mean pulmonary artery pressure under hyperoxia in comparison to normoxia and hyperoxia</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of the cardiac output under hyperoxia in comparison to normoxia and hyperoxia</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of the partial pressure of carbon dioxide under hyperoxia in comparison to normoxia and hyperoxia</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of the partial pressure of oxygen under hyperoxia in comparison to normoxia and hyperoxia</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>PH-Patients</arm_group_label>
    <description>Patients with mean pulmonary artery pressure &gt;25mmHg and a pulmonary arterial wedge pressure &lt;15mmHg during right heart catheterisation, which are diagnosed as having pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients with clinically indicated right heart catheterisation (because of dyspnea or other signs of PH), but had no PH (no elevated mean pulmonary artery pressure (mPAP &lt;20mmHg)).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypoxia and Hyperoxia</intervention_name>
    <description>10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>PH-Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that come to our PH referral center for evaluation of PH and undergo a clinically&#xD;
        indicated right heart catheterisation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinically indicated right heart catheterisation&#xD;
&#xD;
          -  diagnosis of pulmonary arterial hypertension or chronic thromboembolic pulmonary&#xD;
             hypertension or control without pulmonary hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hemodynamically unstable&#xD;
&#xD;
          -  partial pressure of Oxygen &lt; 7.3kPa&#xD;
&#xD;
          -  no informed consent&#xD;
&#xD;
          -  pulmonary hypertension due to left heart disease, chronic lung disease or&#xD;
             miscellaneous (Groups II, III and V) according to Galié ERJ 2015&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Ulrich Somaini, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UniversityHospital Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UniversityHospital Zurich, Department of Pulmonology</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary arterial hypertension</keyword>
  <keyword>Chronic thromboembolic pulmonary hypertension</keyword>
  <keyword>Hypoxia</keyword>
  <keyword>Hyperoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

